Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex...

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology
• Genetic Basis of Cardiac Disease

Background:

• Hypertrophic Cardiomyopathy (HCM) is a common genetic heart disorder characterized by left ventricular hypertrophy.
• It is a leading cause of sudden cardiac death in young individuals, often presenting without prior symptoms.
• The clinical presentation of HCM is highly variable, ranging from asymptomatic to severe symptoms and arrhythmias.

Purpose of the Study:

• To review the molecular mechanisms underlying Familial Hypertrophic Cardiomyopathy (FHC) pathogenesis.
• To illustrate the link between specific gene mutations in sarcomeric proteins and disease development.
• To highlight potential therapeutic targets for FHC.

Main Methods:

• Review of existing literature on genetic mutations in sarcomeric protein genes linked to FHC.
• Focus on mutations in key sarcomeric components: thick filament (beta MyHC), thin filament (cTnT and Tm), and associated proteins (MyBP-C).
• Integration of biochemical, biophysical, and physiological experimental findings to elucidate disease mechanisms.

Main Results:

• Over 270 mutations in nine sarcomeric protein genes are associated with FHC, indicating significant genetic heterogeneity.
• Specific gene mutations, affecting proteins like beta MyHC, cTnT, Tm, and MyBP-C, are linked to distinct prognoses and clinical variability.
• Experimental studies reveal how these protein dysfunctions contribute to the pathogenesis of HCM.

Conclusions:

• Understanding the functional consequences of sarcomeric gene mutations is crucial for comprehending FHC.
• The diverse genetic landscape of FHC contributes to its varied clinical phenotypes.
• Elucidation of these molecular mechanisms provides a foundation for developing future therapeutic interventions for FHC.